The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.

Gutenberg, A; Lumenta, C B; Braunsdorf, W E K; Sabel, M; Mehdorn, H M; Westphal, M; Giese, A

Gutenberg, A; Lumenta, C B; Braunsdorf, W E K; Sabel, M; Mehdorn, H M; Westphal, M; Giese, A.

Affiliation

Gutenberg A; Department of Neurosurgery, University Medical Center, Johannes Gutenberg University Mainz, Langenbeckstrasse 1, 55131, Mainz, Germany.

J Neurooncol ; 113(2): 163-74, 2013 Jun.

Article in En | MEDLINE | ID: mdl-23535992

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Brain Neoplasms/drug therapy; Glioma/drug therapy; Carmustine/administration & dosage; Clinical Trials as Topic; Dacarbazine/administration & dosage; Dacarbazine/analogs & derivatives; Humans; Prognosis; Temozolomide

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Glioma Type of study: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: J Neurooncol Year: 2013 Document type: Article

Fulltext

XML

PubMed Links

Search on Google